TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07197866: An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Sponsor: Teva Branded Pharmaceutical Products R&D LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$6,374,400

Rescue Site Savings

+$4,216,400

Unlock Full NCT07197866 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07197866 Rescue Dossier →